Albert Wu , MD, PhD, a recognized  advocate of using stem cell therapy to treat eye conditions, will advise company’s development of ocular tissue rejuvenation therapeutics

MOUNTAIN VIEW, Calif. , Aug. 22, 2022 /PRNewswire/ — Change Biotechnologies, a cell revitalization company developing novel mRNA medicines in order to cure untreatable, age-related conditions, today announced that Albert Wu , MD, PhD, will oversee its development associated with ophthalmic therapeutic products as an advisor to the company.

A board-certified ophthalmologist and fellowship-trained specialist in oculoplastic and orbital surgery, Wu’s academic work has focused on developing treatments for vision loss and vision disease.

At Turn Bio, he can shepherd work on TRN-004, a formulation to rejuvenate ocular tissues, including corneal, limbal plus conjunctival epithelial cells, as well as corneal endothelial cells. Preclinical results show the formulation reduces inflammation, oxidative stress, and cell senescence.

TRN-004 is a tailored protein cocktail to rejuvenate targeted cells within the eyesight. It is produced using Turn Bio’s unique mRNA-based ERA™ (Epigenetic Reprogramming of Aging) platform.

“Albert’s life mission will be to transform ophthalmology by making regenerative medicine an accepted treatment regarding people worldwide suffering from diseases associated with the eyes, ” said Anja Krammer , the company’s CEO. “His vision and experience will help us redefine how eye doctors deal with age-related vision conditions for which no real cure exists. ”

Wu has nearly two decades of experience with ophthalmology and cellular biology. He has been honored by the National Institutes of Health, American Society of Ophthalmic Plastic plus Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, the particular University of Washington and Yale University .

“Our work offers the potential to revolutionize eye care to preserve patients’ eyesight and, ultimately, restore it, ” stated Wu. “The ability to produce cell revitalization therapies plus deliver them with pinpoint accuracy offers enormous promise to millions of people around the world whose sight has been compromised by untreatable problems. ”

Wu received his bachelor’s degree in Molecular Biophysics and Biochemistry through Yale College , their medical level and doctoral degree in Molecular plus Cellular Biology from the particular University associated with Washington . They have co-authored 55 articles on his research discoveries and has contributed to textbooks on ophthalmology and ophthalmologic oncology. He is a frequent presenter at national plus international medical conferences.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is the pre-clinical-stage organization centered on repairing tissue in the mobile level. The company’s proprietary mRNA platform technology, ERA™, restores optimal gene expression simply by combatting the effects of aging within the epigenome. This restores the cells’ capability to prevent or treat disease, heal or even regenerate tissue and fight incurable chronic diseases.

The company is currently completing pre-clinical study on tailored therapies targeting indications in dermatology and immunology, and also developing therapies for ophthalmology, osteo-arthritis and the muscular system. For more information, see www.turn.bio .

FOR MORE INFORMATION, CONTACT:

Jim Martinez , rightstorygroup
[email protected]   or (312) 543-9026

SOURCE Turn Biotechnologies, Inc.

Leave a Reply

Your email address will not be published.